AR115537A1 - Terapia combinada con una vacuna neoantigénica - Google Patents

Terapia combinada con una vacuna neoantigénica

Info

Publication number
AR115537A1
AR115537A1 ARP190101629A ARP190101629A AR115537A1 AR 115537 A1 AR115537 A1 AR 115537A1 AR P190101629 A ARP190101629 A AR P190101629A AR P190101629 A ARP190101629 A AR P190101629A AR 115537 A1 AR115537 A1 AR 115537A1
Authority
AR
Argentina
Prior art keywords
peptide
combined therapy
neoepitope
nivolumab
ipilimumab
Prior art date
Application number
ARP190101629A
Other languages
English (en)
Original Assignee
Neon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neon Therapeutics Inc filed Critical Neon Therapeutics Inc
Publication of AR115537A1 publication Critical patent/AR115537A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/876Skin, melanoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un método para tratar o prevenir una neoplasia en un sujeto humano que lo necesita caracterizado porque comprende administrar a un sujeto que lo necesita: (a) un primer componente que comprende (i) un péptido que comprende un neoepitope de una proteína, (ii) un polinucleótido que codifica para el péptido, (iii) una o más CPA que comprenden el péptido o el polinucleótido que codifica para el péptido o (iv) un receptor de células T (TCR) específico del neoepitope en complejo con una proteína HLA; y (b) un segundo componente que comprende por lo menos dos inhibidores, en donde los al menos dos inhibidores comprenden: (i) nivolumab y un anticuerpo agonista anti-CD40, o (ii) nivolumab e ipilimumab, o (iii) ipilimumab y un anticuerpo agonista anti-CD40.
ARP190101629A 2018-06-12 2019-06-12 Terapia combinada con una vacuna neoantigénica AR115537A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862684013P 2018-06-12 2018-06-12

Publications (1)

Publication Number Publication Date
AR115537A1 true AR115537A1 (es) 2021-01-27

Family

ID=68843592

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101629A AR115537A1 (es) 2018-06-12 2019-06-12 Terapia combinada con una vacuna neoantigénica

Country Status (5)

Country Link
US (1) US20210386856A1 (es)
EP (1) EP3807320A4 (es)
AR (1) AR115537A1 (es)
TW (1) TW202035446A (es)
WO (1) WO2019241306A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295241A (en) * 2020-02-10 2022-10-01 Univ Johns Hopkins Cancer immunotherapy using allogeneic and tumor-specific t-cell and cd4-cell transfusion
WO2024020472A1 (en) * 2022-07-20 2024-01-25 Biontech Us Inc. Combination therapy with neoantigen vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194701A1 (en) * 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
CN106573981A (zh) * 2014-08-12 2017-04-19 鳄鱼生物科学公司 利用抗cd40抗体的组合疗法
CN113791220A (zh) * 2014-09-10 2021-12-14 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台

Also Published As

Publication number Publication date
EP3807320A4 (en) 2022-03-23
US20210386856A1 (en) 2021-12-16
EP3807320A2 (en) 2021-04-21
TW202035446A (zh) 2020-10-01
WO2019241306A3 (en) 2020-01-23
WO2019241306A9 (en) 2020-09-03
WO2019241306A2 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
CO2019010698A2 (es) Vacunas de peptidos
CO2019009234A2 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
BR112019003866A2 (pt) adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite)
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CL2017002686A1 (es) Métodos para tratar o prevenir dolor de cabeza por migraña
CL2020000498A1 (es) Composiciones farmacéuticas que contienen anticuerpos contra la glicoproteína del virus ébola. (divisional solicitud 201701920)
CL2019003142A1 (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso.
CL2018001611A1 (es) Adenovirus del grupo b que codifica un anticuerpo o fragmento anti-tcr-complejo
BR112019022495A2 (pt) Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação
BR112018072915A2 (pt) peptídeo cíclico isolado e composição farmacêutica
PH12018502652A1 (en) Combination therapies
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
CL2023002252A1 (es) Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista
AR099698A1 (es) Anticuerpos contra el c5 que tienen farmacocinética mejorada
BR112016012506A8 (pt) combinações farmacêuticas, seus usos, e uso de um portador de dados
AR107303A1 (es) Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
BR112015021392A2 (pt) uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
EA201891946A1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
PE20161152A1 (es) Anticuerpos y metodos de uso
CL2018000377A1 (es) Mecanismo de resistencia a inhibidores de bromodominio bet
AR115537A1 (es) Terapia combinada con una vacuna neoantigénica
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
AR111360A1 (es) Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas

Legal Events

Date Code Title Description
FB Suspension of granting procedure